You searched for "floaters"

566 results found

Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema

Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...

Intravitreal dexamethasone implant for diabetic macular oedema

The authors report on the three-year outcomes of the Ozurdex Dexamethasone (DEX) intravitreal implant multi-centre trial for the treatment of diabetic macular oedema (DME). Patients with DME (best-corrected vision of 20/50 to 20/200 and central retinal thickness of ≥300µm) were...

First systematic review of COVID-19 colonisation of ocular tissues and secretions

The authors present the first systematic review summarising all the data regarding SARS-CoV-2 colonisation of ocular and periocular tissues and secretions. They reviewed all publications between December 2019 to April 2020 in the Cochrane Library, Medline, World of Science and...

Overview of RoP in a Cyprus population

This was the first epidemiology study of retinopathy of prematurity (RoP) in Cyprus, aiming to validate their criteria for RoP screening. This involved a retrospective review of discharge letters of all infants in RoP screening from January 2023 to December...

Better eye health would boost UK economy by £10bn - almost double the value of the UK’s film and TV industry, research finds

Better eye health would bring a £10 billion boost to the UK economy each year, almost twice the value of the TV and film industry, new research released this World Sight Day has found.

Invitation issued to world leaders for first-ever Global Summit for Eye Health

Prime Minister Gaston Browne has announced that Antigua and Barbuda will host the first ever Global Summit for Eye Health on 2 November 2026. Announcing the Summit, Prime Minister Browne also extended the invitation to Heads of Government, ministers and...

Contemporary glaucoma therapy: spoilt for choice

The goal of glaucoma management is to prevent visual loss and disease progression in the patient’s lifetime through effective lowering of intraocular pressure (IOP), the primary modifiable risk factor in glaucoma. Sustained and consistent IOP reduction is key to halting...

Childhood glaucoma

When a child is given a diagnosis of glaucoma, the impact upon that child and their family is enormous; equivalent to the diagnosis of a cancer [14]. This previously published article (2019) outlines the knowledge, techniques and approaches that offer...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

In conversation with Robert Johnston

Robert Johnston. What is your current role with Medisoft? Clinical Director, i.e. I head up the analysis for and design of Medisoft’s ophthalmology electronic medical records (EMR) product. I don’t program: all coding is done by Medisoft’s team of computer...

Ambient scribes: The silent revolution

Clinical practice is in the midst of a profound digital transformation with a new wave of technology gaining increasing prominence: ambient scribes. These AI-powered tools streamline documentation by converting doctor–patient conversations into structured clinical notes in near real time. Healthcare...

Conference Preview: OOC 2025

Leading us into July this year will be the 108th Oxford Ophthalmological Congress (OOC), the longest-standing congress dedicated to ophthalmology in the UK. This year, the OOC has attracted the largest number of abstracts it has ever seen in its...